Identification of a mutated receptor-like protein tyrosine phosphatase κ as a novel, class II HLA-restricted melanoma antigen

Journal of Immunology

Volumn 170, Issue 12, 2003, Pages 6363-6370

  Novellino, Luisa ^a   Renkvist, Nicolina ^a,c   Rini, Francesca ^a   Mazzocchi, Arabella ^a   Rivoltini, Licia ^a   Greco, Angela ^a   Deho, Paola ^a   Squarcina, Paola ^a   Robbins, Paul F ^b   Parmiani, Giorgio ^a   Castelli, Chiara ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; MELANOMA ANTIGEN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE KAPPA; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CELL CLONING; ENZYME ANALYSIS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LYMPH NODE METASTASIS; LYMPHOCYTE CLONE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

EID: 0038618831     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.12.6363     Document Type: Article

References (42)

1. Parmiani, G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94:805.
2. Marincola, F. M., E. M. Jaffee, D. J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181.
3. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
4. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199.
5. + T lymphocytes. Proc. Natl. Acad. Sci. 96:2982.
6. + T helper cell responses in tumor immunity. Immunol. Lett. 74:75.
7. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
8. van Bergen, J., M. Camps, R. Offringa, C. J. Melief, F. Ossendorp, and F. Koning. 2000. Superior tumor protection induced by a cellular vaccine carrying a tumorspecific T helper epitope by genetic exchange of the class II-associated invariant chain peptide. Cancer Res. 60:6427.
9. Toes, R. E., S. P. Schoenberger, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10:443.
10. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol. 20:17.
11. Hiltbold, E. M., and P. A. Roche. 2002. Trafficking of MHC class II molecules in the late secretory pathway. Curr. Opin. Immunol. 14:30.
12. Lennon-Duménil, A. M., A. H. Bakker, P. Wolf-Bryant, H. L. Ploegh, and C. Lagaudrière-Gesbert. 2002. A closer look at proteolysis and MHC-class-II-restricted antigen presentation Curr. Opin. Immunol. 14:15.
13. Renkvist, N., C. Castelli. P. F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:3.
14. + T cells in antitumor immunity. Trends Immunol. 22:269.
15. Mazzocchi, A., W. J. Storkus, C. Traversari, P. Tarsini, M. J. Maeurer, L. Rivoltini, C. Vegetti, F. Belli, A. Anichini, G. Parmiani, and C. Castelli. 1996. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J. Immunol. 157:3030.
16. + cyto-toxic T lymphocyte clone which specifically recognizes HLA-A2 molecule. Scand. J. Immunol. 35:487.
17. Castelli, C., A. Mazzocchl, F. Rini, P. Tarsini, L. Rivoltini, M. Maio, G. Gallino, F. Belli, and G. Parmiani. 1998. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients. Eur. J. Immunol. 28:1143.
18. Zhang, Z. Y. 2002. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 42:209.
19. Yang, Y., M. C. Gil, E. Y. Choi, S. H. Park, K. H. Pyun, and H. Ha. 1997. Molecular cloning and chromosomal localization of a human gene homologous to the murine R-PTP-κ, a receptor-type protein tyrosine phosphatase. Gene 186:77.
20. Fuchs, M., T. Muller, M. M. Lerch, and A. Ullrich. 1996. Association of human protein-tyrosine phosphatase κ with members of the armadillo family. J. Biol. Chem. 271:16712.
21. Neel, B. G., and N. K. Tonks. 1997. Protein-tyrosine phosphatases in signal transduction. Curr. Opin. Cell Biol. 9:193.
22. Hunter, T. 1995. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signalling. Cell 80:225.
23. Petrone, A., and J. Sap. 2000. Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting? J. Cell Sci. 113:2345.
24. Sap, J., Y. P. Jiang, D. Friedlander, M. Grumet, and J. Schlessinger. 1994. Protein receptor tyrosine phosphatase R-PTP-κ mediates homophilic binding. Mol. Cell. Biol. 14:1.
25. Zondag, G. C., G. M. Koningstein, Y. P. Jiang. J. Sap, W. H. Moolenaar, and M. F. Gebbink. 1995. Homophilic interactions mediated by receptor tyrosine phosphatases μ and κ: a critical role for the novel extracellular MAM domain. J. Biol. Chem. 270:14247.
26. Zhang, Y., R. Siebert, P. Matthiesen, Y. Yang, H. Ha, and B. Schlegelberger. 1998. Cytogenetical assignment and physical mapping of the human R-PTP-κ gene (PTPRK) to the putative tumor suppressor gene region 6q22.2-q22.3. Genomics 51:309.
27. Guan, X. Y., H. E. Zhang, H. Zhou, J. S. Sham, J. M. Fung, and J. M. Trent. 2002. Characterization of a complex chromosome rearrangement involving 6q in a melanoma cell line by chromosome microdissection. Cancer Genet. Cytogenet. 134:65.
28. Maitra, A., A. F. Gazdar, T. O. Moore, and A. Y. Moore. 2002. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi. Hum. Pathol. 33:191.
29. McArdle, L., M. Rafferty, G. M. Maelandsmo, O. Bergin, C. J. Farr, P. A. Dervan, S. O'Loughlin, M. Herlyn, and D. J. Easty. 2001. Protein tyrosine phosphatase genes downregulated in melanoma. J. Invest. Dermatol. 117:1255.
30. + T cells on HLA class II molecules. Cancer Res. 60:4855.
31. + T cell responses. J. Immunol. 163:5820.
32. + T-cell response to hepatitis 8 virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J. Virol. 71:2241.
33. Hickling, J. K., C. M. Fenton, K. Howland, S. G. Marsh, and J. B. Rothbard. 1990. Peptides recognized by class I restricted T cells also bind to MHC class II molecules. Int. Immunol. 2:435.
34. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965.
35. + T cells. J. Exp. Med. 189:757.
36. Yang, S., G. P. Linette, S. Longerich, and F. G. Haluska. 2002. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol. 169:531.
37. + T cells. J. Exp. Med. 189:1659.
38. Wolfel, T., M. Hauer, J. Schneider, M. Serrano. C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
39. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
40. + T cells: its role in extracellular matrix formation and tumor metastasis. J. Exp. Med. 195:1397.
41. Baurain, J. F., D. Colau, N. van Baren, C. Landry, V. Martelange, M. Vikkula, T. Boon, and P. G. Coulie. 2000. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 164:6057.
42. Karanikas, V., D. Colau, J. F. Baurain, R. Chiari, J. Thonnard, I. Gutierrez-Roelens, C. Goffinet, E. V. Van Schaftingen, P. Weynants, T. Boon, and P. G. Coulie. 2001. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res. 61:3718.